Odyssey, an artificial intelligence lab building world models, today announced it has raised $310 million in early-stage funding at a $1.45 billion valuation. Natural Capital led, and Amazon.com Inc., ...

An angry Musk has taken his business elsewhere, and has urged other companies to follow suit. Credit...Illustration by George Wylesol Supported by By Michael Steinberger Michael Steinberger spoke to ...

WASHINGTON — Vice President JD Vance defended the terms of the Iran peace deal on Tuesday, saying a proposed $300 billion reconstruction fund would not be available “unless they totally transform ...

Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled drug design. While ...

ADELPHI, Md. – Army scientists achieved a major milestone in quantum sensing technology that could transform how electromagnetic signals are detected on the battlefield. For the first time, scientists ...

Congressional candidate Maureen Galindo (D-TX) said she would convert an ICE detention center into a “prison for American Zionists,” writing in a post last week that the center would perform ...

UnitedHealth Group Inc. is tracking how often some employees use artificial intelligence tools as part of a push to embed the technology throughout its operations, according to people familiar with ...

An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say.

SAN JOSE, Calif.--(BUSINESS WIRE)--Tessera Labs today announced $60 million in oversubscribed funding led by Andreessen Horowitz (a16z) to accelerate its mission of bringing AI-native automation to ...

Greysun is the Lead Guides Editor at GameRant, where he oversees game help coverage for everything from the biggest AAA releases to standout indie and live-service titles. Professionally, Greysun has ...

Wall Street has placed a big bet on GLP-1 drugs. When Walmart’s U.S. CEO, John Furner, told Bloomberg in October 2023 that customers on Ozempic were buying “slightly less calories,” packaged-food ...